Treatment of In-Stent Restenosis 2 Study
Launched by UNIVERSITY HOSPITAL OSTRAVA · Sep 11, 2018
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
Current therapy for in-stent restenosis (ISR) is based on the drug-eluting stents (DES) or drug-eluting balloon catheters (DEB). In clinical practice, paclitaxel is used as an effective antiproliferative agent loaded into DEB (paclitaxel-eluting balloon catheters; PEB).
In contrast to paclitaxel, sirolimus is difficult to deliver on the balloon surface, due to insufficient tissue uptake and shorter tissue retention of limus drugs. It was found that phospholipid-encapsulated sirolimus nanoparticles could be used for coating balloon catheters to provide efficient drug transfer to vessel wall...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with BMS- or DES-ISR (˃50% diameter stenosis; DS)
- • ≥18 years of age
- • willing to sign an Informed consent
- Exclusion Criteria:
- • concomitant diseases with an expected survival time of less than 12 months
- • or that limited the possibility of control coronary aniography (e.g., advanced renal failure).
- • impossibility of long-term (6 months) dual antiplatelet treatment
About University Hospital Ostrava
University Hospital Ostrava is a leading medical research institution located in Ostrava, Czech Republic, dedicated to advancing healthcare through innovative clinical trials and research initiatives. As a prominent sponsor of clinical studies, the hospital combines cutting-edge medical technology with a commitment to patient-centered care, fostering collaborations among multidisciplinary teams of healthcare professionals and researchers. With a focus on ethical standards and regulatory compliance, University Hospital Ostrava aims to contribute to the development of new therapies and improve treatment outcomes across various medical fields. Its robust research infrastructure and dedication to scientific excellence position it as a key player in the advancement of medical knowledge and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ostrava, , Czechia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials